With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Several telehealth companies use that price difference to market their compounded tirzepatide and semaglutide to consumers.

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

Hims & Hers has begun selling GLP-1 drugs - such as brand names like Ozempic and compounded medications that can be customized - which have been used for weight loss. In its letter to shareholders ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...